Efficacy of Adjuvant Immunochemotherapy with Polysaccharide K for Patients with Curatively Resected Colorectal Cancer: a Meta-analysis of Centrally Randomized Controlled Clinical Trials

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2005 Sep 1

PMID 16133112

Citations 23

Authors

Junichi Sakamoto

Satoshi Morita

Koji Oba

Takanori Matsui

Michiya Kobayashi

Hiroaki Nakazato

Yasuo Ohashi

Affiliations

Soon will be listed here.

Abstract

The benefits of immunochemotherapy employing the biological response modifier polysaccharide K (PSK) for patients with curatively resected colorectal cancer was reassessed by means of a meta-analysis of data with center randomization from 1,094 patients enrolled in three clinical trials. In all three trials, patients were followed up for at least 5 years after surgery and enrollment of the last patient and outcomes for standard chemotherapy were compared with those for chemotherapy plus PSK. The endpoints were overall survival and disease-free survival; and intent-to-treat analysis was performed without patient exclusion. Data were analyzed using the weighted average of the individual log hazard ratios. The overall survival risk ratio for all eligible patients was 0.71 (95% confidence interval (CI) : 0.55-0.90; P=0.006), and the disease-free survival risk ratio was 0.72 (95% CI: 0.58-0.90; P=0.003). The results of this meta-analysis suggest that adjuvant immunochemotherapy with PSK can improve both survival and disease-free survival of patients with curatively resected colorectal cancer.

Citing Articles

Experimental Models in Unraveling the Biological Mechanisms of Mushroom-Derived Bioactives against Aging- and Lifestyle-Related Diseases: A Review.

Sharika R, Mongkolpobsin K, Rangsinth P, Prasanth M, Nilkhet S, Pradniwat P Nutrients. 2024; 16(16).

PMID: 39203820 PMC: 11357205. DOI: 10.3390/nu16162682.

Current Progress of EMT: A New Direction of Targeted Therapy for Colorectal Cancer with Invasion and Metastasis.

Tan Z, Sun W, Li Y, Jiao X, Zhu M, Zhang J Biomolecules. 2022; 12(12).

PMID: 36551152 PMC: 9775097. DOI: 10.3390/biom12121723.

Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer.

Pilkington K, Wieland L, Teng L, Jin X, Storey D, Liu J Cochrane Database Syst Rev. 2022; 11():CD012053.

PMID: 36445793 PMC: 9707730. DOI: 10.1002/14651858.CD012053.pub2.

Mushroom Polysaccharide-Assisted Anticarcinogenic Mycotherapy: Reviewing Its Clinical Trials.

Sivanesan I, Muthu M, Gopal J, Oh J Molecules. 2022; 27(13).

PMID: 35807336 PMC: 9267963. DOI: 10.3390/molecules27134090.

Gemcitabine and doxorubicin in immunostimulatory monophosphoryl lipid A liposomes for treating breast cancer.

Wu D, Zhao Z, Kim J, Razmi A, Wang L, Kapate N Bioeng Transl Med. 2021; 6(1):e10188.

PMID: 33532588 PMC: 7823124. DOI: 10.1002/btm2.10188.

References

Parkin D, Bray F, Devesa S . Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001; 37 Suppl 8:S4-66. DOI: 10.1016/s0959-8049(01)00267-2. View

Hayashida Y, Kurimoto S, Yamamoto N . Effect of lymphokine-activated killer cells on human retinoblastoma cells (Y-79) in vitro: enhancement of the activity by a polysaccharide preparation, krestin. Biochem Biophys Res Commun. 1991; 174(1):107-14. DOI: 10.1016/0006-291x(91)90492-p. View

Okuzawa M, Shinohara H, Kobayashi T, Iwamoto M, Toyoda M, Tanigawa N . PSK, a protein-bound polysaccharide, overcomes defective maturation of dendritic cells exposed to tumor-derived factors in vitro. Int J Oncol. 2002; 20(6):1189-95. View

Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T . Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer. 2004; 90(5):1003-10. PMC: 2409633. DOI: 10.1038/sj.bjc.6601619. View

Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T . Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350(23):2343-51. DOI: 10.1056/NEJMoa032709. View

Fisher M, Yang L . Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res. 2002; 22(3):1737-54. View

Takashima S, KINAMI Y, Miyazaki I . [Clinical effect of postoperative adjuvant immunochemotherapy with the FT-207 suppository and PSK in colorectal cancer patients. Colorectal Cancer Chemotherapy Group in Hokuriku]. Gan To Kagaku Ryoho. 1988; 15(8):2229-36. View

Matsunaga K, Hosokawa A, Oohara M, Sugita N, Harada M, Nomoto K . Direct action of a protein-bound polysaccharide, PSK, on transforming growth factor-beta. Immunopharmacology. 1998; 40(3):219-30. DOI: 10.1016/s0162-3109(98)00045-9. View

Yoshikawa R, Yanagi H, Hashimoto-Tamaoki T, Morinaga T, Nakano Y, Noda M . Gene expression in response to anti-tumour intervention by polysaccharide-K (PSK) in colorectal carcinoma cells. Oncol Rep. 2004; 12(6):1287-93. View

10.

Ishigaki H, Satoh S, Saitoh S, Yoshida Y, Ebina T, Satoh T . [An autopsy case of rectal cancer receiving cisplatin at total dose of 3.250 mg and platinum concentrations in autopsy tissue samples]. Gan To Kagaku Ryoho. 1989; 16(12):3805-8. View

11.

Hirose K, Zachariae C, Oppenheim J, Matsushima K . Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res. 1990; 9(4):475-83. View

12.

Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J . Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994; 343(8906):1122-6. DOI: 10.1016/s0140-6736(94)90233-x. View

13.

Sakamoto J, Ohashi Y, Hamada C, Buyse M, Burzykowski T, Piedbois P . Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol. 2004; 22(3):484-92. DOI: 10.1200/JCO.2004.04.065. View

14.

Kanoh T, Saito K, Matsunaga K, Oguchi Y, Taniguchi N, Endoh H . Enhancement of the antitumor effect by the concurrent use of a monoclonal antibody and the protein-bound polysaccharide PSK in mice bearing a human cancer cell line. In Vivo. 1994; 8(2):241-5. View

15.

Mukai M, Tokunaga N, Yasuda S, Mukohyama S, Kameya T, Ishikawa K . Long-term survival after immunochemotherapy for juvenile colon cancer with peritoneal dissemination: a case report. Oncol Rep. 2000; 7(6):1343-7. DOI: 10.3892/or.7.6.1343. View

16.

Sakamoto J, Hamada C, Kodaira S, Nakazato H, Ohashi Y . Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials. Jpn J Clin Oncol. 1999; 29(2):78-86. DOI: 10.1093/jjco/29.2.78. View

17.

Sakamoto J, Kato J, Yasue M . [Surgery and multidisciplinary treatment for colorectal cancer]. Gan To Kagaku Ryoho. 1998; 25(2):208-15. View

18.

Kimura K, Tuchiya S, Yasutomi M, Ohkawa T, Hirose T, Tani C . [Comparison of surgical therapy and combined irradiation in rectal cancer--first report, effect of irradiation on the tumor. Study Group of Surgical Therapy and Combined Irradiation in Rectal Cancer]. Gan To Kagaku Ryoho. 1989; 16(9):3161-72. View

19.

Suo J, Tanaka N, Hizuta A, Yunoki S, Orita K . Suppression of hepatic natural killer activity by liver metastasis of cancer and restoration of killer activity by oral administration of a Basidomycetes-derived polysaccharide, PSK. Acta Med Okayama. 1994; 48(5):237-42. DOI: 10.18926/AMO/31113. View

20.

Nio Y, Tsubono M, Tseng C, Morimoto H, Kawabata K, Masai Y . Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer. Biotherapy. 1992; 4(2):117-28. DOI: 10.1007/BF02171756. View